FREIENBACH, Switzerland – EffRx Pharmaceuticals SA is pleased to announce the appointment of Dr. Nathalie Véron as Director Technical Operations & Qualified Person. She is responsible for overseeing all technical operations activities at EffRx, such as manufacturing relations, supply chain and quality management.
Prior to joining EffRx, Dr. Véron has held various local and global, cross-functional leadership positions in Manufacturing Science and Technology at F. Hoffmann-La Roche, Technical Operations. In addition, she significantly contributed to Digital Supply Chain and Quality Transformation projects in the pharmaceutical industry.
Dr. Véron is a pharmacist by education, who graduated from the University of Freiburg, Germany. She holds a PhD in Biology from the Free University Berlin, Germany and has over 10 years of experience as a Biomedical Scientist.
“We are excited to have such an experienced and dynamic person joining our diverse team,” said Mr. Lorenzo Bosisio, CEO of EffRx Pharmaceuticals. “Nathalie’s capabilities will play an important role in the direct commercialization of niche and orphan medicines by EffRx as well as to further advance our operational standards.”
Dr. Véron commented, “I am excited to contribute to the growth and value creation of this dynamic, innovative company, given the smart and passionate people in the Company and its expanding portfolio of products for new and orphan therapeutic areas. I believe that the company’s approach to deliver innovative, high quality products allows us to make a difference for the patients.”
About EffRx Pharmaceuticals
EffRx Pharmaceuticals is a commercial-stage pharmaceutical company focused on the late stage development and commercialization of prescription medications for niche and orphan indications. The business model is centered around providing superior clinical and commercial value propositions for physicians, payers and patients.
EffRx pro-actively seeks in-licensing opportunities for Europe in niche therapeutic areas, with a primary interest for rare diseases, where EffRx has received an orphan drug designation (ODD) from the FDA for a pipeline asset.
EffRx’s go-to-market competence is proven by the development, launch and lucrative expansion of Binosto® in a highly competitive European market. Our lead commercialized product, Binosto® for the treatment of osteoporosis, is marketed in the US as well as selected European and Asian countries.